1/64
Looks like no tags are added yet.
Which cells are most at risk of damage by non-specific chemotherapy agents?
cells which have a high turnover (i.e. divide the most rapidly)
E.g. mucosal lining of the GI tract
E.g. hair follicles
E.g. blood cells
Side effects of chemotherapy based on the type of cell affected
Mucosal lining of the GI tract - diarrhoea and vomiting
Hair follicles - alopecia
Blood cells - anaemia and neutropenia
Nausea and Vomiting
3 phases of nausea and vomiting
Acute - occurs following chemotherapy
Decayed - occurs following chemotherapy
Anticipatory - occurs prior to chemotherapy
Nausea and Vomiting
Acute nausea and vomiting
Occurs during the first 24 hours immediately after chemotherapy
Nausea and Vomiting
Delayed nausea and vomiting
Occurs between 24 hours and up to 6/7 days later
Nausea and Vomiting
Anticipatory nausea and vomiting
A conditioned response where a patient experiences nausea or vomiting before a chemotherapy treatment session even begins
Nausea and Vomiting
Effects of uncontrolled nausea and vomiting
Reduced quality of life for the patient
Dehydration
If N+V becomes problematic, the only way to administer other medications is via a subcutaneous syringe driver
Admission to hospital
Dose reductions of chemotherapy
Patient may refuse treatment
Nausea and Vomiting
What needs to be ensured within a chemotherapy combination regimen?
Ensure there is not 2 or more agents with particularly pronounced nausea and vomiting
Anti-emetics
Anti-emetic guidelines for prophylaxis of chemotherapy and radiotherapy induced nausea and vomiting


Anti-emetics
What is the difference between the 2 high risk emetogenic potential categories?
If patient taking an anthracycline + cyclophosphamide OR cisplatin at a dose of 70/m2 or more » considered high risk and acrepitant is indicated
If patient is NOT taking anthracycline + cyclophosphamide OR cisplatin at a dose of 70/m2 or more » acrepitant is not indicated
Anti-emetics
Acrepitant
NK1 inhibitor
Fosacrepitant is the salt of acrepitant that can be administered intravenously
Acrepitant is only licensed to be used in conjunction with dexamethasone and a 5-HT3 antagonist
Where an Acrepitant is used as part of an anti-emetic regimen (top row high risk emotogenic potential), dexamethasone dose is reduced

Anti-emetics
How do we determine the emetic risk of chemotherapy?
Example:
A chemotherapy regimen of Carboplatin (dose: 5AUC) with Cetuximab
Carboplatin >= 4AUC = high emesis risk
Cetuximab = low emesis risk
Go with the highest causing risk
This regimen has a high emetic risk. This determines which anti-emetic we prescribe
Example:
A chemotherapy regimen consisting of 2 drugs with a moderate emetic risk
This regimen has a high emetic risk

Diarrhoea
Main chemotherapy agents associated with diarrhoea
Capecitabine
Irinotecan
Tyrosine kinase inhibitors e..g imatinib
Immunotherapy
Diarrhoea
Treatment
Loperamide (except in immunotherapy patients)
Oral rehydration therapy
Codeine (added to / to replace loperamide)
Ocreotide (somatostatin analogue, reduces intestinal motility)
Atropine (given prophylactically in regimens containing irinotecan)
Diarrhoea
When is ocreotide only used?
If loperamide is ineffective
In grade 3 - 4 diarrheoa
Diarrhoea
When is atropine used?
given prophylactically in regimens containing irinotecan
Mucositis
What causes mucositis?
Damage to the mucosal lining of the GI tract
Mucositis
Main chemotherapy agents associated with mucositis?
Flourouracil - particularly when it is given as a continuous infusion
Capecitabine
Methotrexate (high dose)
Mucositis
Problems associated with mucositis
Difficult for patients to look after their gums and maintain good oral hygiene, risk of cutting gums when brushing teeth - so risk of infection
Decreases oral intake - in severe cases: patients may require IV fluids, patients may be prescribed total parenteral nutrition
Pain
Mucositits
Recommendations to prevent mucositis
Use a soft toothbrush
Maintain good oral hygeine
Use a mouthwash to reduce risk of infection e.g. Corsodyl, Nystatin
Mucositis
Treatment
Difflam mouthwash - steroid containing mouthwash, reduces inflammation
Sucralfate mouthwash - able to swallow so coats the mouth and oesophagus
Lignocaine mouthwash - local anaesthetic that numbs any pain, however can make it difficult for patients to feel food while eating which can lead to gum or lip cuts
Paracetamol
Severe cases: morphine, dose reductions
Palifermin - human keratinocyte growth factor, not widely available on the NHS, normally used for bone marrow transplant induced mucositis
Alopecia
Which chemotherapy agents are most associated with Alopecia?
Not all chemotherapy agents cause alopecia
Most associated with:
Anti-microtubule agents e.g. taxanes, vincas
Anthracyclines
Methotrexate
Alopecia
Extent of chemotherapy induced Alopecia
Not necessarily complete hair loss - can be thinning of the hair
Not all hair on the body is lost
Happens gradually and reverses at the end of treatment
Alopecia
Advice to minimise hair loss
Avoid hair dye
Avoid perms
Avoid plaits
Avoid using hairdryers
Alopecia
Treatment
No pharmacological treatments available
However, can consider scalp cooling
20 - 30 mins before chemotherapy
Cold liquid continuously circulates through a cap that is placed on the patient’s head
This reduces the surface temperature of the scalp, causing the capillaries around the hair follicles to constrict
This reduces blood supply to the hair follicle, so chemotherapy has less chance of reaching the hair follicle
This reduces chance of hair loss
Alopecia
What is a drawback of scalp cooling
Scalp cooling impacts the circulation of the chemotherapy
Cannot use scalp cooling if patient has a cancer that has spread to the CNS e.g. brain metastasis
Risk that constriction of the blood vessels will reduce impact of chemotherapy on the cancer in the CNS
Extravasation
What is extravasation?
Where a parenteral fluid goes into the subcutaneous tissue instead of the vein
Leakage of the fluid into the surrounding tissue can cause damage
Extravasation
What is important to consider if we suspect extravasation has occurred ?
Whether the chemotherapy agent is acidic or alkaline
Acidic or alkaline agents are more likely to cause damage
We check the SPC for each agent to determine the risk
Extravasation
How can extravasation be prevented?
Trained nurses
Using appropriate lines or cannulas
Assessing the appropriateness of the vein that the chemo is going into
Avoid administering fluids into the back of the hand as veins are smaller and less strong
Instead, use veins in the pit of the elbow
Extravasation
How long after treatment can extravasation occur?
During or a couple of hours after treatment
Extravasation
What is an important complication that extravasation can cause?
Tissue necrosis
Any signs of pain / burning
Needs to be treated ASAP
Extravasation
Categories of chemotherapy drugs based on their potential to cause harm if extravasation occurs
Vesicants
Causes serious effects such as tissue necrosis if extravasation occurs
Further subdivided:
DNA-Binding - greatest potential for causing significant tissue damage (binds to DNA of healthy cells)
Non-DNA-Binding
Irritants
Causes pain, redness or swelling but less likely to cause serious effects such as necrosis if extravasation occurs
Non-vesicants
Low potential for causing harm if extravasation occurs

Laboratory Results
Which lab results should be monitored in patients undergoing chemotherapy?
Full Blood Counts (FBCs) - neutrophils, white blood cell count, platelets, Hb
Renal function - creatinine, urea
Hepatic function - LFTs
Cardiac function - echocardiogram to see LFEF
U & Es
Tumour biomarkers e.g. PSA levels
Laboratory Results
Example of chemo agent which can cause significant cardiac damage
Anthracyclines
Bone Marrow Suppression
Signs of reductions in red or white blood cell counts
Unexplained bleeding (thrombocytopenia)
Unexplained bruising (thrombocytopenia)
Sore throat (neutropenia)
Fever (neutropenia)
Fatigue (drop in Hb causing anaemia)
Breathlessness (drop in Hb causing anaemia)
Neutropenia
What is neutropenia?
A lower than normal level of neutrophils - neutrophils are a type of white blood cell
Neutropenia
Effect on treatment of neutrophil count is too low
Treatment is delayed
Neutropenia
2 types of neutropenia
Neutropenic sepsis
Absolute neutrophil count of 0.5 × 109/L or lower
AND
Temperature of greater than 38°C AND any signs of sepsis
Febrile neutropenia
Absolute neutrophil count of 0.5 × 109/L or lower
AND
Temperature of greater than 38°C but NO signs of sepsis
Neutropenia
Consequences of neutropenia
Medical emergency
Patient immediately admitted for broad-spectrum antibiotic therapy: piperacillin + tazobactam + gentamicin
Possibly consider granulocyte-colony stimulating factor (GCSF)
Neutropenia
Effects of GCSF
Stimulates production of neutrophils
Reduces duration of neutropenia and incidence of febrile neutropenia
Neutropenia
How can granulocyte-colony stimulating factor (GCSF) be used in relation to chemotherapy?
Primary prevention of neutropenia
To prevent neutropenia from happening in the first place
E.g. for patients taking docetaxel or anthracyclines, GCSF is given automatically a few days after treatment
Secondary prevention of neutropenia
For patients who develop neutropenia after chemotherapy treatment where no GCSF prophylaxis was originally used e.g. after stem-cell therapy
Patient is given the same dose of chemotherapy again BUT GCSF prescribed for secondary prevention of neutropenia
Thrombocytopenia
What is thrombocytopenia?
Reduced platelet count
Thrombocytopenia
Consequences of thrombocytopenia
Delays in treatment to allow platelet count to recover
Dose reductions
Thrombocytopenia
Treatment
If severe, patients can be given pools of platelets - however recovery in platelet count is short lived
Withdrawal of chemotherapy and cessation of any antiplatelets e.g. aspirin, LMWH is usually enough
Anaemia
What is anaemia?
Reduction in Hb levels
Anaemia
Symptoms
Fatigue, breathlessness
Anaemia
Frequency
Most chemo agents can cause anaemia
Anaemia
Treatment / Management
Iron tablets
Blood transfusions if Hb is critically low
Anaemia
Drawback of blood transfusions for treatment of anaemia
Some patients can become transfusion-dependent which can lead to iron overload
Tumour Lysis Syndrome
What is tumour lysis syndrome?
A metabolic syndrome
Malignant (cancer) cells break down
Causing intracellular contents to leak into the bloodstream
Tumour Lysis Syndrome
Signs
Hyperuricaemia (high uric acid)
Hyperphosphataemia
Hyperkalaemia
Hypocalcaemia
(Cell lysis leads to the release of electrolytes into the bloodstream)
Tumour Lysis Syndrome
Consequences
Change in electrolyte levels in the blood can lead to:
Renal damage
Arrhythmias
Seizures
Death
Tumour Lysis Syndrome
Which cancers is tumour lysis syndrome is most commonly associated with?
Cancers with high proliferation rates and tumour burden (‘bulky disease’)
Cancers that are fast growing are more likely to have more cells
Cancers that are larger are more likely to have more cells
So when the first cycle of chemotherapy is given, there is a higher risk of tumour lysis syndrome because the volume of cancer cells being impacted is the highest
More cancer cells being targeted by chemo = more cells are at risk of undergoing lysis
Tumour Lysis Syndrome
Cancers with a high proliferation and high tumour burden that are more at risk of tumour lysis syndrome
Hodgkin’s lymphoma
Acute myeloid leukaemia
Tumour Lysis Syndrome
Additional risk factors for tumour lysis syndrome?
Increasing age
Existing abnormal levels of electrolytes (uric acid, phosphate, potassium, calcium)
Impaired renal function - harder to clear electrolytes
Tumour Lysis Syndrome
Treatment / Management
Allopurinol
Xanthane oxidase inhibitor
Reduces production of uric acid (most problematic electrolyte imbalance)
This prevents uric acid crystallisation in the kidneys
Rasburicase
Urate from uric acid is metabolised by rasburicase into allantoin
Allantoin is more soluble than uric acid, which makes it easier for the body to eliminate
Management of hyperkalaemia
In extreme cases, dialysis is required
Tumour Lysis Syndrome
Example of ‘bulky disease’

Haemorrhagic Cystitis
Which chemotherapy agents is this side effects most commonly associated with?
Cyclophosphamide
Ifosfamide
Haemorrhagic Cystitis
What causes haemorrhagic cystitis?
Cyclophosphamide is metabolised to produce acrolein
Acrolein can irritate the lining of the bladder
The lining of the bladder is then shed in the urine
This leads to haemorrhagic cystitis
Haemorrhagic Cystitis
Treatment
Mesna
Binds with acrolein in the kidneys, preventing damage to the bladder
Mensa is always given to patients receiving:
Cyclophosphamide doses of 1g/m2 (oral or iv
All doses ofifosfamide
Peripheral Neuropathy
Which chemotherapy agents is peripheral neuropathy most associated with?
Platinum agents
Capecitabine
Vincas
Peripheral Neuropathy
Symptoms
Change in sensation of fingertips / toes
Increased sensitivity
Pain
Numbness
Pins and needles
Muscle weakness
Difficulty handling small objects
Issues with balance, walking, co-ordination
Constipation and bloating
Peripheral Neuropathy
Management
Symptoms are treated as they occur rather than prevented:
Pyridoxine aka Vitamin B6 - 50mg PO TDS
Severe cases: Gabapentin or Pregabalin
Non pharmacological treatment: TENS, Acupuncture

Plantar-Palmar Erythema (PPE)
Management
Emollients - to reduce cracking, dryness
If severe: chemotherapy dose reduction
Cardiotoxicity
Management